Key facts
- The U.S. FDA declined to approve Achieve Life Sciences' drug cytisinicline for nicotine dependence.
- Reasons cited include issues at a third-party manufacturing facility and incomplete final product labeling.
The U.S. Food and Drug Administration declined to approve Achieve Life Sciences' experimental drug cytisinicline for smoking cessation, citing manufacturing facility issues and incomplete labeling. The company plans to resubmit its application in late 2026.
The FDA's decision delays the introduction of a new non-nicotine prescription option for smokers, a market that has been underdeveloped. The outcome impacts Achieve Life Sciences' development pipeline and the availability of alternative smoking cessation treatments.
The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' experimental drug, cytisinicline, intended for treating nicotine dependence in adults. The agency cited unresolved issues identified at a third-party manufacturing facility and incomplete final product labeling as reasons for the decision.
In its complete response letter, the FDA stated that there were no deficiencies related to the drug's clinical efficacy or safety. Cytisinicline is a plant-derived compound designed to reduce nicotine cravings and withdrawal symptoms by targeting nicotine receptors in the brain, offering a non-nicotine prescription alternative to existing options like Pfizer's Chantix and GSK's Zyban.
Achieve Life Sciences indicated that late-stage trials involving over 1,500 participants demonstrated that cytisinicline was more effective than a placebo in helping adults quit smoking, with benefits observed for up to 24 weeks and no new safety concerns identified in longer-term data. The company had anticipated a complete response letter, as its former third-party manufacturer had received an FDA inspection classification requiring corrective action for general manufacturing matters unrelated to cytisinicline.
The company has since transitioned its manufacturing to Adare Pharma Solutions, a U.S.-based entity. Achieve plans to resubmit its application for cytisinicline in the fourth quarter of 2026, with a potential FDA approval anticipated in the first half of 2027. Analysts view the absence of clinical efficacy or safety deficiencies as a positive sign for future approvability, noting the significant market potential for a new smoking-cessation option.